ALSO NOTED: Paxil back on the market; Tarceva gets European recommendation; and much more...

> GlaxoSmithKline has returned Paxil CR to the market, three months after regulators found manufacturing problems at three of its facilities. Story

> A European drug panel has recommended Roche's Tarceva for lung cancer. Story

> The European Medicines Agency has recommended the continued suspension of Pfizer's Bextra with new warnings regarding all Cox-2 inhibitors. Story

> Neurobiological Technologies has signed a manufacturing deal with Baxter and Nordmark for a Phase III trial of Viprinex. Release

> Switzerland's Debiopharm and Neovacs have signed an equity and licensing deal for the development of Neovacs' anti-TNF-Alpha product. Release

> The EU's Committee for Medicinal Products for Human Use has recommended approval of Schering's contrast agent, Vasovist. Article

And Finally... Even as pharmaceutical drugs continue their double-digit rise in prices, generic drug prices are remaining steady. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.